Status:
COMPLETED
A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes
Lead Sponsor:
Pfizer
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the efficacy and safety of Aricept in nursing home patients with severe Alzheimer's disease.
Eligibility Criteria
Inclusion
- Probable or possible Alzheimer's disease
- Living in skilled nursing home
Exclusion
- Other types of dementia or psychiatric or neurologic disorders
- Musculoskeletal disease
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2004
Estimated Enrollment :
249 Patients enrolled
Trial Details
Trial ID
NCT00630851
Start Date
October 1 2002
End Date
October 1 2004
Last Update
March 5 2015
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Fritsla, Sweden, Sweden, 510 29
2
Pfizer Investigational Site
Alunda, Sweden, 747 30
3
Pfizer Investigational Site
Aneby, Sweden, 578 21
4
Pfizer Investigational Site
Avesta, Sweden, 774 82